Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 4/20 | 0.46 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | MPL | P40238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060527 | 0.94 | MAPT (0.50) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL23704805 | 0.94 | MAPT (0.50) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL30058874 | 0.93 | MAPT (0.49) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL23705338 | 0.93 | MAPT (0.49) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL30058927 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL30058867 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL23704781 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL23704887 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL23704783 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 | |
| SCHEMBL30058883 | 0.92 | MAPT (0.47) | MAPTALDH1A1THRBROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MAPT 2074/4885ALDH1A1 2571/4885THRB 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.